Ranbaxy Laboratories Limited has received import permission for marketing the US FDA approved product Gliadel (polifeprosan 20 with carmustine implant) Wafer for the treatment of newly diagnosed high-grade malignant gliomas & recurrent glioblastoma multiforme. Ranbaxy has signed an exclusive licensing agreement with BioPro Pharmaceutical, Inc, (BioPro) USA to promote and market Gliadel Wafer in India.
The details can be read here.
No comments:
Post a Comment